Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
